Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating reissued by research analysts at Oppenheimer in a research note issued on Monday.

VNDA has been the subject of a number of other reports. Zacks Investment Research cut Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 19th. BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Piper Jaffray Companies increased their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, September 14th. Finally, ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $21.50.

Vanda Pharmaceuticals (NASDAQ VNDA) traded down $0.05 during mid-day trading on Monday, reaching $14.20. The company had a trading volume of 625,700 shares, compared to its average volume of 618,500. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99. The firm has a market cap of $630.11, a PE ratio of -44.38 and a beta of 1.29.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. During the same period last year, the firm posted ($0.01) EPS. The business’s revenue was up 7.3% on a year-over-year basis. equities analysts expect that Vanda Pharmaceuticals will post -0.44 earnings per share for the current year.

In other news, CFO James Patrick Kelly sold 9,155 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total value of $140,529.25. Following the transaction, the chief financial officer now directly owns 144,721 shares in the company, valued at approximately $2,221,467.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the transaction, the insider now owns 1,031,848 shares in the company, valued at $15,787,274.40. The disclosure for this sale can be found here. Insiders sold a total of 209,483 shares of company stock worth $3,205,205 over the last quarter. Corporate insiders own 7.60% of the company’s stock.

Large investors have recently bought and sold shares of the company. Legal & General Group Plc boosted its position in shares of Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares during the last quarter. Kopp Investment Advisors LLC bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth $196,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter worth $277,000. Voya Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 29.7% in the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its position in shares of Vanda Pharmaceuticals by 46.3% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 6,487 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2018/01/10/vanda-pharmaceuticals-vnda-rating-reiterated-by-oppenheimer.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.